Related Experiment Video

Updated: Sep 15, 2025

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.3K

Global Research Trends and Collaborative Networks in Cellular Therapy for Crohn's Disease: A Systematic Review and

Tunç Akkoç1,2,3

  • 1Department of Immunology, Marmara University School of Medicine, İstanbul, Türkiye. tuncakkoc@marmara.edu.tr.

Advances in Experimental Medicine and Biology
|July 16, 2025
PubMed

Insights

This bibliometric analysis reveals a significant increase in Crohn

Area of Science:

  • Gastroenterology and Immunology
  • Biomedical Research Trends
  • Bibliometric Analysis

Background:

  • Crohn's disease (CD) is a chronic gastrointestinal inflammatory condition with recurrent relapses and remissions.
  • Understanding the research landscape of CD cellular therapy is crucial for advancing treatment strategies.

Purpose of the Study:

  • To conduct a comprehensive 30-year bibliometric analysis of global research on cellular therapy for Crohn's disease.
  • To identify key trends, influential institutions, and publication patterns in this field.

Main Methods:

  • Data sourced from the Web of Science database (1992-2023) using specific search terms for Crohn's disease and cellular therapy.
  • Analysis involved R Studio Bibliometric to assess publication volume, citations, contributing journals, and author contributions.
  • Inclusion criteria limited the study to English-language articles and reviews.

Main Results:

  • 559 documents from 258 sources were identified, with a notable publication surge from 2009, peaking in 2019.
  • The USA was the leading country for publications and citations, followed by Spain, China, Italy, and Canada.
  • Prominent research institutions included the Cleveland Clinic Foundation, Sun Yat-Sen University, and Mayo Clinic.

Conclusions:

  • Cellular therapy research for Crohn's disease has expanded significantly, reflecting advancements in treatment.
  • Despite research progress, a broad clinical consensus on cellular therapy for CD remains elusive.
  • This bibliometric study underscores the dynamic evolution of cellular therapy research in managing Crohn's disease.
Abstract

Keywords:
BibliometricsCell- and tissue-based therapyCrohn’s diseaseSystematic review

More Related Videos

A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC11:40

A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC

Published on: January 30, 2018

13.2K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
392
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
426
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
204
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
198